Pulmatrix price to sales ratio PULM

Market value divided by revenue over the last twelve months, since 2015.

Today, Oct 23, 2026: n/m; not a meaningful number
Last meaningful: 2.5×; Aug 2025
10-year median: 3.5×
10-year range: 0.6× to 127×
Peer median: 1.4×

Pulmatrix's price to sales ratio is not a meaningful number today: revenue for one or more of the four quarters through 2026-06-30 is missing, so twelve months can't be added up.

It was last meaningful in Aug 2025, at 2.5×.

On the days it had one over the last ten years, its median was 3.5×, from 0.6× in May 2024 to 127× in Nov 2018.

Price to sales ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2025	2.5×	2.2×	4.2×
2024	2.3×	0.6×	2.4×
2023	1.0×	0.9×	3.3×
2022	2.9×	2.5×	4.3×
2021	3.7×	3.5×	7.0×
2020	3.3×	3.0×	4.5×
2019	51.5×	27.6×	101×
2018	92.0×	29.8×	127×
2017	52.6×	9.5×	75.7×
2016	8.7×	8.3×	68.0×
2015	74.3×	74.3×	95.3×

Against its peers

Companies in Healthcare nearest Pulmatrix's size, closest first, today.

Company	Price to sales ratio
PULMPulmatrix	n/m
OXBROXBRIDGE RE HOLDINGS	2.8×
EDUCEducational Development	0.4×
GTIMGood Times Restaurants	0.1×
MDRRMedalist Diversified	1.6×
BCGBinah Capital	0.1×
VIPVulcan Infrastructure & Power	0.4×
MXCMexco Energy	3.0×
CKXCKX Lands	31.0×
MSGMMotorsport Games	1.5×
ATCHAtlasClear	1.2×
Peer median	1.4×

What the price to sales ratio tells you

Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.

Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.

More on Pulmatrix

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.